Understanding Frailty and the Challenges of Aging
As people grow older, maintaining strength, mobility, and independence becomes increasingly important. However, some individuals experience a condition known as frailty; which involves declining physical strength, reduced endurance, fatigue, and greater difficulty performing everyday activities.
Frailty is more than simply getting older. It reflects a decrease in the body’s ability to handle physical stress and recover from challenges, potentially increasing the risk of falls, hospitalization, and loss of independence.
Researchers are now exploring whether regenerative medicine could help address some of the biological processes associated with frailty. A 2026 clinical trial published in eBioMedicine investigated whether umbilical cord-derived mesenchymal stem cells could improve physical performance and overall well-being in older adults.
Why Umbilical Cord-Derived Stem Cells?
Umbilical cord-derived mesenchymal stem cells (UC-MSCs) are specialized cells collected from donated umbilical cord tissue following childbirth. These cells are being studied for their ability to influence inflammation, communicate with other cells, and support the body’s natural repair processes.
Rather than simply replacing damaged tissue, UC-MSCs may work by releasing biological signals that help regulate immune activity and create a more supportive environment for cellular function. Because chronic inflammation and reduced cellular resilience are associated with frailty, researchers wanted to investigate whether UC-MSC infusions could offer measurable benefits.
Inside the Clinical Trial
The phase 2 randomized clinical trial took place in Vietnam and involved 148 adults between the ages of 60 and 85 who met established criteria for frailty.
Participants were assigned to two groups:
- UC-MSC group: Received two intravenous stem cell infusions, spaced three months apart, alongside oral supplements.
- Control group: Received the same oral supplements without stem cell infusions.
One participant withdrew before treatment, leaving 147 individuals who completed the nine-month follow-up.
Researchers evaluated several aspects of physical health, including walking speed, balance, muscle strength, fatigue, physical activity, and quality of life. Blood samples were also analyzed for biological markers associated with inflammation and cellular aging.
Encouraging Improvements in Physical Function
The findings showed several positive differences between the UC-MSC group and the control group. One of the most important measures was the Short Physical Performance Battery (SPPB), which evaluates balance, walking speed, and the ability to stand from a chair.
Compared with controls, participants receiving UC-MSCs demonstrated higher physical performance scores throughout follow-up. At three and six months, the adjusted between-group difference was approximately 1.1 points, with a smaller but still statistically significant difference at nine months.
Additional findings included:
- Improved mobility: Participants receiving UC-MSCs completed walking assessments faster.
- Greater muscle strength: Handgrip strength was consistently higher in the treatment group.
- Reduced fatigue: Participants reported less fatigue and greater physical activity.
- Better perceived health: Quality-of-life assessments favored the UC-MSC group.
These findings suggest that UC-MSC therapy may help improve certain aspects of physical function associated with frailty.
Looking Beyond Physical Improvements
Researchers also investigated changes occurring at the cellular level. Participants receiving UC-MSCs showed reductions in several inflammatory markers, including IL-6 and TNF-alpha, which are involved in immune signaling and inflammation.
The study also identified temporary improvements in certain measures of mitochondrial function. Mitochondria help cells produce energy, making them particularly relevant to research involving aging and physical endurance.
Although these biological findings are encouraging, they do not establish that the treatment reverses cellular aging. Instead, they offer possible clues about how UC-MSC therapy may influence processes associated with frailty.
Safety and Treatment Tolerability
Safety was an important part of the trial, particularly because the participants were older adults. No serious adverse events were reported in either group. Ten UC-MSC recipients experienced a total of 12 mild treatment-related events, including headaches, dizziness, and chest discomfort.
All treatment-related symptoms resolved without lasting complications during the study.
What These Findings Could Mean for Regenerative Medicine
This study provides an interesting look at how regenerative medicine might support physical health during aging.
Unlike therapies designed to treat a single injured joint or organ, UC-MSC therapy was investigated for its potential effects on several interconnected aspects of frailty, including mobility, muscle function, inflammation, and energy-related cellular processes.
However, the study was conducted at a single medical center, participants knew which treatment they received, and follow-up lasted only nine months. Larger, blinded clinical trials will be needed to confirm the benefits, evaluate longer-term safety, and understand how durable the improvements may be.
Overall, these findings offer encouraging evidence that umbilical cord-derived stem cells deserve further investigation as a potential approach to supporting physical resilience and quality of life in older adults.
Source
Nguyen LT, et al. Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial. eBioMedicine. 2026;127:106268. DOI: 10.1016/j.ebiom.2026.106268. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC13123506/
Related Treatment Pages